Truist raised the firm’s price target on Quest Diagnostics (DGX) to $205 from $195 and keeps a Hold rating on the shares. The company posted solid Q3 results ahead of consensus expectations on the top and bottom-lines with FY25 nudged higher as its core trends remain solid with organic volumes ahead of the firm’s thinking, better revenue, and a continued tailwind from testing, with the organic revenue guide raised, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley
- Quest Diagnostics price target raised to $195 from $190 at Barclays
- Quest Diagnostics Reports Strong Q3 2025 Results
- Quest Diagnostics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Quest Diagnostics price target raised to $215 from $200 at Jefferies